TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
TG TherapeuticsTG Therapeutics(US:TGTX) Globenewswire·2026-01-14 05:25

Preliminary total global full year 2025 revenue of approximately 616millionPreliminaryBRIUMVIU.S.fourthquarterandfullyear2025netproductrevenueofapproximately616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately 182 million and 594million,respectivelyFullYear2026targettotalglobalrevenueofapproximately594 million, respectivelyFull Year 2026 target total global revenue of approximately 875-900 million, including BRIUMVI U.S. net product revenue of approximately $825-850 million NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics), today announced prelimina ...